14563-41-8

Basic information

• Product Name: 4-(2,4-dimethoxy-phenyl)-4-oxo-butyric acid methyl ester
• Synonyms: 4-(2,4-dimethoxy-phenyl)-4-oxo-butyric acid methyl ester
• CAS NO: 14563-41-8
• Molecular Weight: 252.267
• Mol File: 14563-41-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(2,4-dimethoxy-phenyl)-4-oxo-butyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,4-dimethoxy-phenyl)-4-oxo-butyric acid methyl ester(14563-41-8)
• EPA Substance Registry System: 4-(2,4-dimethoxy-phenyl)-4-oxo-butyric acid methyl ester(14563-41-8)

Safety Data

• Hazardous Substances Data: 14563-41-8(Hazardous Substances Data)

Upstream product

• 14617-06-2 3-(2',4'-dimethoxybenzoyl)propionic acid 
• 77-78-1 dimethyl sulfate 
• 151-10-0 1,3-Dimethoxybenzene 
• 67-56-1 methanol 

Downstream Products

• 156868-45-0 2,4-methoxy-α,α-dimethylbenzenebutanol 
• 13335-55-2 4-(2,4-dihydroxy-phenyl)-4-oxo-butyric acid methyl ester 
• 42907-96-0 β-(2-hydroxy-4-methoxybenzoyl)propionic acid methyl ester 
• 856075-91-7 4-(5-bromo-2,4-dimethoxy-phenyl)-2-methoxy-4-oxo-butyric acid methyl ester 
• 69163-57-1 4-(5-bromo-2,4-dimethoxy-phenyl)-4-oxo-butyric acid methyl ester 
• 63213-40-1 4-(5-bromo-2,4-dimethoxy-phenyl)-4-oxo-butyric acid 
• 156868-43-8 2,4-dimethoxybenzenebutanoic acid methyl ester 

Relevant articles and documents

Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors

The involvement of μ-calpain in neurological disorders, such as stroke and Alzheimer's disease has attracted considerable interest in the use of calpain inhibitors as therapeutic agents. 4-Aryl-4-oxobutanoic acid amide derivatives 4 were designed as acyclic variants of μ-calpain inhibitory chromone and quinolinone derivatives. Of the compounds synthesized, 4c-2, which possesses a 2-methoxymethoxy group at the phenyl ring and a primary amide at the warhead region most potently inhibited μ-calpain (IC50 = 0.34 μM). Our findings suggest that the 4-aryl-4-oxobutanoic acid amide derivatives should be considered as a new family of μ-calpain inhibitors.

The reduction of beta-benzoyl-propionic acids of the resorcinol series

-